Russell Dahl

Russell is the CEO of Neurodon. He is also the founder, President, and a member of the Board of Directors. Dr. Dahl has extensive experience leading translational programs in various therapeutic areas. Originally trained as a synthetic organic chemist, his biopharma experience ranges from leading hit-to-lead screening efforts through the oversight of FDA submissions for small molecule therapeutics. Under his leadership, Neurodon has identified multiple first-in-class development candidates for various pipeline indications.

Having almost 2 decades of medicinal chemistry and drug discovery experience, Dr. Dahl has contributed to many programs that have reached clinical trials at DuPont Pharmaceuticals, Alanex (now Pfizer), BMS, Vertex Pharmaceuticals, and various biotech companies.

Dr. Dahl has also founded or advised multiple startup companies developing therapeutics in diverse areas such as cancer, hearing loss, CNS disorders, and heart failure.

Dr. Dahl has held tenure-track professor positions in medicinal chemistry and neuroscience and has co-authored over 100 publications. He is an inventor on over 60 patents or applications in therapeutics and chemistry. He received his Ph.D. in Organic Chemistry from the University of California, San Diego as a DuPont Pharmaceuticals Fellow and has additional training in Molecular Pharmacology from Stanford.